Anti-fibrotic effects of L-2-oxothiazolidine-4-carboxylic acid via modulation of nuclear factor erythroid 2-related factor 2 in rats
![]() ![]() |
Kim, In-Hee
(Department of Internal Medicine, Chonbuk National University Medical School and Hospital)
Kim, Dae-Ghon (Department of Internal Medicine, Chonbuk National University Medical School and Hospital) Hao, Peipei (Research Institute of Clinical Medicine, Chonbuk National University Medical School and Hospital) Wang, Yunpeng (Research Institute of Clinical Medicine, Chonbuk National University Medical School and Hospital) Kim, Seong-Hun (Department of Internal Medicine, Chonbuk National University Medical School and Hospital) Kim, Sang-Wook (Department of Internal Medicine, Chonbuk National University Medical School and Hospital) Lee, Seung-Ok (Department of Internal Medicine, Chonbuk National University Medical School and Hospital) Lee, Soo-Teik (Department of Internal Medicine, Chonbuk National University Medical School and Hospital) |
1 | Lee, S., Moon, S. O., Kim, W., Sung, M. J., Kim, D. H., Kang, K. P., Jang ,Y. B., Lee, J. E., Jang, K. Y., Lee, S. Y. and Park, S. K. (2006) Protective role of L-2-oxothiazolidine-4-carboxylic acid in cisplatin-induced renal injury. Nephrol. Dial. Transplant. 21, 2085-2095. DOI ScienceOn |
2 | Scheuer, P. J. (1991) Classification of chronic viral hepatitis: a need for reassessment. J. Hepatol. 13, 372-374. DOI ScienceOn |
3 | Iimuro, Y., Bradford, B. U., Yamashina, S., Rusyn, I., Nakagami, M., Enomoto, N., Kono, H., Frey, W., Forman, D., Brenner, D. and Thurman, R. G. (2000) The glutathione precursor L-2-oxothiazolidine-4-carboxylic acid protects against liver injury due to chronic enteral ethanol exposure in the rat. Hepatology 31, 391-398. DOI ScienceOn |
4 | Bataller, R. and Brenner, D. A. (2005) Liver fibrosis. J. Clin. Invest. 115, 209-218. DOI ScienceOn |
5 | Breitkopf, K., Haas, S., Wiercinska, E., Singer, M. V. and Dooley, S. (2005) Anti-TGF-beta strategies for the treatment of chronic liver disease. Alcohol. Clin. Exp. Res. 29(11 Suppl), S121-S131. DOI ScienceOn |
6 | George, J., Roulot, D., Koteliansky, V. E. and Bissell, D. M. (1999) In vivo inhibition of rat stellate cell activation by soluble transforming growth factor beta type II receptor: a potential new therapy for hepatic fibrosis. Proc. Natl. Acad. Sci. U.S.A. 96, 12719-12724. DOI ScienceOn |
7 | Muriel, P. (2009) Role of free radicals in liver diseases. Hepatol. Int. 3, 526-536. DOI ScienceOn |
8 | Singal, A. K., Jampana, S. C. and Weinman, S. A. (2011) Antioxidants as therapeutic agents for liver disease. Liver Int. 31, 1432-1438. DOI ScienceOn |
9 | Nieto, N., Friedman, S. L. and Cederbaum, A. I. (2002) Stimulation and proliferation of primary rat hepatic stellate cells by cytochrome p450 2e1-derived reactive oxygen species. Hepatology 35, 62-73. DOI ScienceOn |
10 | Mates, J. M. (2000) Effects of antioxidant enzymes in the molecular control of reactive oxygen species toxicology. Toxicology 153, 83-104. DOI ScienceOn |
11 | Farombi, E. O., Shrotriya, S., Na, H. K., Kim, S. H. and Surh, Y. J. (2008) Curcumin attenuates dimethylnitrosamine-induced liver injury in rats through Nrf2-mediated induction of heme oxygenase-1. Food Chem. Toxicol. 46, 1279-1287. DOI ScienceOn |
12 | Kawada, N., Seki, S., Inoue, M. and Kuroki, T. (1998) Effect of antioxidants, resveratrol, quercetin, and N-acetylcysteine, on the functions of cultured rat hepatic stellate cells and Kupffer cells. Hepatology 27, 1265-1274. DOI |
13 | Tahan, G., Tarcin, O., Tahan, V., Eren, F., Gedik, N., Sahan, E., Biberoglu, N., Guzel, S., Bozbas, A., Tozun, N. and Yucel, O. (2007) The effects of N-acetylcysteine on bile-duct ligation-induced liver fibrosis in rats. Dig. Dis. Sci. 52, 3348-3354. DOI |
14 | Yamazaki, H., Oda, Y., Funae, Y., Imaoka, S., Inui, Y. and Guengerich, F. P. (1992) Participation of rat liver cytochrome P450 2E1 in the activation of N-nitrosdimethylamine and N-nitrosodiethylamine to products genotoxic in an acetyltransferase-overexpressing Salmonella typhimurium strain. Carcinogenesis 13, 979-985. DOI ScienceOn |
15 | Aleksunes, L. M. and Manautou, J. E. (2007) Emerging role of Nrf2 in protecting against hepatic and gastrointestinal disease. Toxicol. Pathol. 35, 459-473. DOI ScienceOn |
16 | Leaf, C. D. and Pace, G. W. (1994) Development of a novel glutathione repleting agent, L-2-oxothiazolidine-4-caboxylic acid (Procysteine). Exp. Opin. Invest. Drugs. 3, 1293-1302. DOI |
17 | Klaassen, C. D. and Reisman, S. A. (2010) Nrf2 the rescue: effects of the antioxidative/electrophilic response on the liver. Toxicol. Appl. Pharmacol. 244, 57-65. DOI ScienceOn |
18 | Jaiswal, A. (2004) Nrf2 signaling in coordinated activation of antioxidant gene expression. Free Radic. Biol. Med. 36, 1199-1207. DOI ScienceOn |
19 | Meister, A., Anderson, M. E. and Hwang, O. (1986) Intracellular cysteine and glutathione delivery systems. J. Am. Coll. Nutr. 5, 137-151. DOI |
20 | Mesina, J. E., Page, R. H., Hetzel, F. W. and Chopp, M. (1989) Administration of L-2-oxothiazolidine-4-caroxylate increases glutathione levels in rat brain. Brain Res. 478, 181-183. DOI ScienceOn |
21 | Tilg, H. and Diehl, A. M. (2000) Cytokines in alcoholic and nonalcoholic steatohepatitis. N. Engl. J. Med. 343, 1467-1476. DOI ScienceOn |
22 | Friedman, S. L. (2000) Molecular regulation of hepatic fibrosis, an integrated cellular response to tissue injury. J. Biol. Chem. 275, 2247-2250. DOI ScienceOn |
23 | Bataller, R. and Brenner, D. A. (2001) Hepatic stellate cells as a target for the treatment of liver fibrosis. Semin. Liver. Dis. 21, 437-451. DOI ScienceOn |
24 |
Gressner, A. M. and Weiskirchen, R. (2006) Modern pathogenetic concepts of liver fibrosis suggest stellate cells and TGF- |
25 | Urtasun, R., Conde de la Rosa, L. and Nieto, N. (2008) Oxidative and nitrosative stress and fibrogenic response. Clin. Liver Dis. 12, 769-790. DOI ScienceOn |
![]() |